TLiCR
TRANSLATIONAL LUNG CANCER RESEARCH
AN OPEN ACCESS JOURNAL FOCUSING ON CLOSING THE GAP BETWEEN "BENCH AND BEDSIDE"

Annual Report 2019

Editorial Office
Email: editor@tlcr.org
Outline of the Report

1. Basic Information
2. Honorary Editors-in-Chief
3. Editors-in-Chief
4. Editorial Board Members
5. Publication: Number, Article Types, Internationality
6. Website Visits in 2019
7. Pageviews of Website in 2019
9. Most Cited Articles
10. Focused Issues Published in 2019
11. Upcoming Focused Issues and Guest Editors in 2020
12. Introduction of the Publisher AME
1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- **Impact Factor: 4.806**
- Indexed by Science Citation Index Expanded (SCIE), PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases, MDlinx
- Published quarterly (Mar. 2012-Dec 2012), and bimonthly (2013-)
- The first international journal focusing on closing the gap between “Bench and Bedside” in lung cancer and related thoracic diseases.
2. Honorary Editors-in-Chief

Fred R. Hirsch, MD, PhD
Center for Thoracic Oncology, Tisch Cancer Institute at Mount Sinai, USA

Yi-Long Wu
Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
3. Editors-in-Chief

Yong Song, MD, PhD
General Hospital of Eastern Theater Command, China

Caicun Zhou, MD, PhD
Shanghai Pulmonary Hospital, China

Rafael Rosell, MD, PhD
Dexeus University Institute, Spain
4. Editorial Board Members

147 in Totality, Including:
- Two Honorary Editors-in-Chief
- Three Editors-in-Chief
- Four Associate Editors-in-Chief
- One Editor Emeritus
- Two Associate Editor

135 Editorial Board Members

Geographical Distribution of Editorial Board Members

Updated on Dec 31, 2019
Till Dec 31 2019, totally 979 articles were published in TLCR.

The number of publication was increased from 2012-2014, yet it has kept a stability between 2014 and 2017, and has an obvious growth in 2018 and 2019.
5. Publication: Diverse Article Types

TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Original Article/Guideline/Consensus, Review Article, and Editorial Commentary.
5. Publication: Internationality

In total, 173 Corresponding Authors from 24 countries and regions contributed to TLCR in 2019, with the majority from the USA and China.
6. Website Visits in 2019

According to the data collected from Google Analytics, there are altogether 109,142 users and 288,752 pageviews in 2019. Readers who visited TLCR website are from diverse countries, with the majority from United States, followed by China, India, United Kingdom and Japan.

<table>
<thead>
<tr>
<th>Country</th>
<th>Sessions</th>
<th>% Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>56,242</td>
<td>38.09%</td>
</tr>
<tr>
<td>China</td>
<td>18,857</td>
<td>12.77%</td>
</tr>
<tr>
<td>India</td>
<td>9,734</td>
<td>6.59%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>7,845</td>
<td>5.31%</td>
</tr>
<tr>
<td>Japan</td>
<td>7,647</td>
<td>5.18%</td>
</tr>
<tr>
<td>Australia</td>
<td>4,066</td>
<td>2.75%</td>
</tr>
<tr>
<td>Canada</td>
<td>3,950</td>
<td>2.68%</td>
</tr>
<tr>
<td>Italy</td>
<td>3,246</td>
<td>2.20%</td>
</tr>
<tr>
<td>South Korea</td>
<td>3,142</td>
<td>2.13%</td>
</tr>
<tr>
<td>Spain</td>
<td>2,819</td>
<td>1.91%</td>
</tr>
</tbody>
</table>
7. Pageviews of Website in 2019

Note: Data were collected from google analytics.

Note: Data were collected from PubMed Central.
## 9. Most Cited Articles

<table>
<thead>
<tr>
<th>Corresponding Author</th>
<th>Article Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett G.M. Hughes</td>
<td>Targeted therapy for non-small cell lung cancer: current standards and the promise of the future</td>
</tr>
<tr>
<td>Farhad Islami</td>
<td>Global trends of lung cancer mortality and smoking prevalence</td>
</tr>
<tr>
<td>Jeryl Villadolid</td>
<td>Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities</td>
</tr>
<tr>
<td>Shaker A. Mousa</td>
<td>Non-small cell lung cancer: current treatment and future advances</td>
</tr>
<tr>
<td>SMing-Sound Tsao</td>
<td>Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review</td>
</tr>
<tr>
<td>Takashi Kohno</td>
<td>Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer</td>
</tr>
<tr>
<td>Po Yee Yip</td>
<td>Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer</td>
</tr>
<tr>
<td>Jyoti Malhotra</td>
<td>Current state of immunotherapy for non-small cell lung cancer</td>
</tr>
<tr>
<td>Rodney E. Shackelford</td>
<td>Epigenetics in non-small cell lung cancer: from basics to therapeutics</td>
</tr>
<tr>
<td>Marcello Tiseo</td>
<td>Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</td>
</tr>
</tbody>
</table>
10. Focused Issues Published in 2019

“Stereotactic Body Radiation Therapy for Thoracic Malignancies” edited by

Isabelle Choi, MD
University of Maryland School of Medicine, Baltimore, USA

Charles B. Simone II, MD
University of Maryland School of Medicine, Baltimore, USA
10. Focused Issues Published in 2019

“Tobacco Control and Lung Cancer Screening” edited by

Jacek Jassem, MD, PhD
Medical University of Gdansk,
Gdańsk, Poland
10. Focused Issues Published in 2019

“Recent Developments in Radiotherapy for Lung Cancer” edited by

Alexander V. Louie1, MD, PhD, FRCPC
Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, Canada

Houda Bahig, MD, PhD, FRCPC
Centre Hospitalier de l'Université de Montréal, Montreal, Canada

Drew Moghanaki, MD, MPH
Atlanta Veterans Affairs Health Care System & Winship Cancer Institute, Emory University, Decatur, USA
10. Focused Issues Published in 2019

“Tobacco Control and Lung Cancer Screening” edited by

Lucio Crinò, Angelo Delmonte
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Maroncelli, Meldola (FC), Italy
11. Upcoming Focused Issues and Guest Editors in 2020

<table>
<thead>
<tr>
<th>Focused Issue</th>
<th>Guest Editor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma: What We know and What We Do Not Know in 2020</td>
<td>Michele Carbone&lt;br&gt;University of Hawai’i Cancer Center, Honolulu, USA</td>
</tr>
<tr>
<td>Lung Cancer MDT Care</td>
<td>Emily Stone&lt;br&gt;St Vincent’s Hospital, Sydney, Australia</td>
</tr>
<tr>
<td>Looking for chimeras in NSCLC: widen therapeutic options targeting oncogenic fusions</td>
<td>Silvia Novello&lt;br&gt;University of Turin, Turin, Italy&lt;br&gt;Francesco Passiglia&lt;br&gt;San Luigi Hospital, Orbassano, Italy</td>
</tr>
<tr>
<td>New developments in lung cancer diagnosis and pathological patient management strategies</td>
<td>Helmut H. Popper&lt;br&gt;Medical University of Graz, Graz, Austria</td>
</tr>
<tr>
<td>Multimodal management of locally advanced N2 non-small cell lung cancer</td>
<td>Mariano Provencio&lt;br&gt;Hospital Universitario Puerta de Hierro, Madrid, Spain</td>
</tr>
<tr>
<td>Lung cancer screening</td>
<td>Paul van Schil &amp; Annemiek Snoeckx&lt;br&gt;Antwerp University Hospital, Edegem, Belgium</td>
</tr>
</tbody>
</table>
## 11. Upcoming Focused Issues and Guest Editors

<table>
<thead>
<tr>
<th>Focused Issue</th>
<th>Guest Editor(s)</th>
</tr>
</thead>
</table>
| New era of treatment for unresectable locally advanced non-small cell lung cancer | Steven H. Lin  
The University of Texas MD Anderson Cancer Center, Houston, USA  
Zhengfei Zhu  
Fudan University Shanghai Cancer Center, Shanghai, China  
Xiaolong Fu  
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China |
| Radiotherapy in thoracic malignancies                   | Jacek Jassem & Rafal Dziadziuszko  
Medical University of Gdańsk, Gdańsk, Poland                                                                                               |
| Immune-checkpoint inhibitors                            | Jordi Remon  
Centro Integral Oncología Clara Campal Barcelona-HM  
Delfos, Barcelona, Spain  
Benjamin Besse  
Medicine Department Thoracic Oncology Unit Gustave Roussy, France                                                                          |
12. Introduction of the Publisher AME

Our Publisher—
AME Publishing Company
www.amegroups.com

• Established in 2009
• Registered in Hong Kong
• 10 offices around the world

• 60+ peer-reviewed journals
  - 13 indexed in SCIE
  - 18 indexed in PubMed/PMC/MEDLINE

• 120+ Medical Books
  - 60+ Medical Books in English
  - 60+ Medical Books in Chinese
Thank You for All Your Support!